Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PAZOPANIB for Atrial fibrillation: Side Effects & Safety Data

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

There are 5 adverse event reports in the FDA FAERS database where PAZOPANIB was used for Atrial fibrillation.

Most Reported Side Effects for PAZOPANIB

Side Effect Reports % Deaths Hosp.
Death 3,767 17.8% 3,764 211
Diarrhoea 2,907 13.7% 213 501
Fatigue 1,883 8.9% 173 315
Nausea 1,879 8.9% 192 413
Malignant neoplasm progression 1,471 6.9% 570 372
Drug ineffective 1,135 5.4% 160 141
Decreased appetite 1,116 5.3% 196 321
Vomiting 1,072 5.1% 153 366
Hypertension 1,004 4.7% 104 271
Malaise 764 3.6% 148 254
Disease progression 739 3.5% 185 82
Asthenia 727 3.4% 161 280
Product use in unapproved indication 724 3.4% 153 60
Weight decreased 697 3.3% 85 168
Hair colour changes 679 3.2% 41 83

Other Indications for PAZOPANIB

Product used for unknown indication (5,026) Renal cancer (3,759) Renal cell carcinoma (2,799) Soft tissue sarcoma (1,400) Metastatic renal cell carcinoma (1,353) Neoplasm malignant (716) Malignant connective tissue neoplasm (417) Renal cancer metastatic (366) Sarcoma (296) Thyroid cancer (264)

Other Drugs Used for Atrial fibrillation

RIVAROXABAN (52,584) DABIGATRAN ETEXILATE (20,492) APIXABAN (10,500) AMIODARONE (9,083) WARFARIN (8,680) EDOXABAN (3,855) ASPIRIN (2,993) DOFETILIDE (2,439) PRADAXA (2,325) METOPROLOL (1,542)

Related Pages

PAZOPANIB Full Profile All Atrial fibrillation Drugs PAZOPANIB Demographics PAZOPANIB Timeline